Ashwagandha
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Ashwagandha is most useful as a stress, sleep, and recovery tool for users whose training or health goals are being dragged down by high cortisol, poor sleep, or chronic stress load.
For ordinary users, the main safety job is proportional: avoid pregnancy, hyperthyroidism, liver disease, oral steroid/hepatotoxic stacks, and stop for liver, thyroid, or mood-warning signals; labs are contextual rather than a default requirement.
Ashwagandha is most useful as a stress, sleep, and recovery tool for users whose training or health goals are being dragged down by high cortisol, poor sleep, or chronic stress load. The testosterone angle is modest and mostly belongs to natural-state, stressed, or low-normal men; it is not a real anabolic substitute.
The main risks are uncommon but real: reversible liver injury in most reported cases, rare severe liver reports, emotional blunting or anhedonia in susceptible users, thyroid stimulation, and HPA-axis suppression with continuous high-dose use. Pregnancy, hyperthyroidism, liver disease, oral steroid stacks, heavy alcohol, and new mood/thyroid/liver warning signs are the stop-or-avoid lanes.
Ashwagandha is one of the few OTC adaptogens with RCT support for cortisol reduction, sleep quality, anxiety, and some performance markers. The value depends on matching the extract to the job: KSM-66 for daytime stress/performance, Sensoril for a more sleep-leaning feel, Shoden for low-dose potency, and raw powder only when variability is acceptable.
High for stress and sleep in responders, mixed for testosterone, and useful but not dramatic for recovery. Poor experiences cluster around emotional blunting, paradoxical stimulation, thyroid sensitivity, and long continuous dosing rather than acute toxicity.
Do not combine with Anadrol (oxymetholone) or other oral 17-alpha-alkylated steroids — compounded hepatotoxicity risk.
Intro
Ashwagandha (Withania somnifera) is an Ayurvedic rasayana herb classified as an adaptogen with over 3,000 years of therapeutic use and one of the strongest OTC supplement evidence bases available — multiple randomized controlled trials support its cortisol-lowering, anxiolytic, sleep-improving, and physical performance effects. Its primary active constituents are withanolides (C-28 steroidal lactones, principally withaferin-A and withanolide-D) operating through HPA axis modulation, GABAergic potentiation, NF-κB inhibition, and Nrf2 activation. In performance and bodybuilding contexts, it is valued for cortisol suppression creating a cleaner hormonal environment on cycle, testosterone support in natural-state users via the cortisol-testosterone seesaw, sleep quality improvement on suppressive compounds, and recovery marker reduction in trained athletes. Bioavailability is approximately 20%, peak plasma at ~2 hours, and withanolide half-life extrapolated at 7–10 hours. Extract type determines the user experience: KSM-66 is a root-only extract standardized around 5% withanolides and usually fits daytime stress, natural-testosterone, and performance stacks at 300–600 mg/day; Sensoril uses root and leaf at higher standardization and often feels more sedating, making it a common sleep/anxiety choice around 250–300 mg/day; Shoden is a higher-potency standardized extract that can be dosed much lower, commonly around 120 mg/day when users want less capsule load; raw bulk powder is the least predictable option because equivalent exposure may require 3–6 g/day with high batch-to-batch variability. These are forms of the same broader herb, not separate compounds, so swapping forms should be treated like changing dose and effect profile. Ashwagandha is not a neutral supplement — it actively modulates neuroendocrine pathways with meaningful risks including uncommon hepatotoxicity, emotional blunting, thyroid stimulation, and rare persistent neurological effects that mainstream wellness marketing systematically ignores.
Observed Effects
Consistent across multiple RCTs: cortisol reduction of 15–30% in chronically stressed adults on 300–600 mg standardized extract for 8–12 weeks.
Significant anxiety reduction on HAM-A and GAD-7 (effect size d ~0.5–0.8). Sleep latency reduction averaging -11 min; total sleep time +30–60 min; subjective sleep quality significantly improved. Muscle mass gains of approximately 1.5 kg vs 0.5 kg placebo in resistance-trained men on 600 mg KSM-66 for 8 weeks (Wankhede et al. 2015, J Int Soc Sports Nutr). VO2max improvement of ~5–15% in both sedentary and trained populations over 8–12 weeks. Testosterone increases of 10–22% in hypogonadal or chronically stressed non-TRT men. Subclinical hypothyroidism normalization with T4/T3 increases at 600 mg/day. Cognitive improvements in reaction time and attention in stressed populations; modest effect on executive function. Female sexual function improvements (FSFI scores) on 300 mg Sensoril twice daily. One important caveat: at least one RCT showed significant cortisol reduction without corresponding improvements in perceived stress — biochemical normalization and subjective relief are dissociable outcomes. Adverse effects include emotional blunting and anhedonia (persistent in a minority, attributed to 5HT1A desensitization), hepatotoxicity (rare but severe, ALT/AST to 4000–5000+), thyroid over-stimulation in euthyroid users, paradoxical stimulation at high doses or morning dosing, and Cushingoid features with continuous high-dose use beyond 12 months.
Field Reports
180-day continuous use: stress resilience and sleep improvement at weeks 4–16, then diminishing returns and mild emotional flattening.
Retrospectively recommends 8–12 week cycling; considers continuous use a mistake. 21-night sleep experiment: sleep latency dropped from 20–30 min to under 2 min; more vivid dreams; morning mood consistently improved; no adverse effects at ~2–3 g/night bulk powder. PSSD/anhedonia case: user took ashwagandha for stress management and developed severe anhedonia — not sedation but loss of pleasure response. Recovery took months. Now advocates magnesium, taurine, glycine as lower-risk alternatives. Detachment at high dose: performance context with documented cortisol reduction but emotional detachment described as 'removed from the situation' — dose-dependent effect some deliberately use in high-pressure environments. Paradoxical stimulation: multiple users experienced increased anxiety and restlessness rather than calm with morning dosing or doses above 600 mg; switching to evening resolved this. On-cycle use: consistent community reports of reduced stress from caloric restriction and less trenbolone-associated anxiety and sleep disruption on KSM-66 600 mg evening. Thyroid interaction: one user needed levothyroxine dose adjusted downward after adding ashwagandha with T4 climbing out of reference range. Major-life-stress buffer: user attributed maintained psychological stability through simultaneous job change, relocation, and medical procedures specifically to ashwagandha.
Community Consensus
In bodybuilding and performance communities, ashwagandha holds a unique position as the most widely stacked OTC adaptogen with actual replicated human RCT data — cortisol suppression, testosterone support, and sleep improvement are credible performance-relevant effects. Three community use cases dominate: (1) cortisol suppression on cycle and during cuts creating a cleaner hormonal environment; (2) natty T support through the cortisol-testosterone seesaw; (3) sleep quality improvement on suppressive compounds particularly trenbolone where night sweats and sleep disruption are common problems. KSM-66 600 mg PM has become the familiar performance-stack default, Sensoril is treated as the more sleep-leaning option, and Shoden is the notable low-dose/high-potency form. A significant counter-narrative has developed among research-oriented community members regarding anhedonia, hepatotoxicity cases, and thyroid stimulation effects — framing ashwagandha as useful but oversold by wellness marketing. The better community read is not that every ordinary user needs routine lab panels; it is that people should not ignore liver, thyroid, pregnancy, medication, and mood red flags just because the product is OTC. Individual educators recommend L-Theanine, Bacopa, Magnesium, and Glycine as lower-risk alternatives specifically for users who want stress relief without ashwagandha's broader neuroendocrine profile.
Risks & Monitoring
Most ordinary users report either no adverse effects or mild GI, sedation, stimulation, or mood-tolerance issues, but ashwagandha has a real uncommon liver-injury signal.
Published cases include large ALT/AST elevations and rare severe liver failure, while typical supplement-associated cases are more often reversible after discontinuation; the practical point is to stop for jaundice, dark urine, itching, right-upper-quadrant discomfort, unexplained fatigue, or abnormal enzymes rather than treating it like a risk-free vitamin. Proposed mechanism: glutathione depletion by withanolides at high concentrations, reversing the Nrf2-antioxidant benefit. Risk is higher with concurrent oral 17-alpha-alkylated steroids, heavy alcohol, existing liver disease, or other hepatotoxic compounds. Emotional blunting and anhedonia affect a minority of users — distinct from therapeutic calm, described as loss of pleasure response rather than reduced anxiety. Attributed to 5HT1A receptor desensitization; can persist weeks to months post-discontinuation. Thyroid over-stimulation: increased T3/T4 is clinically beneficial in subclinical hypothyroidism but can cause jitteriness, palpitations, anxiety, and hair loss in susceptible or euthyroid users; contraindicated in hyperthyroidism and requires prescriber oversight with thyroid medication. Paradoxical stimulation (wired feeling, increased anxiety) occurs in a subset of users, particularly with morning dosing or doses above 600 mg. HPA axis suppression at doses of ~950 mg/day for >12 months — published Cushingoid case; supports cycling daily use rather than running high doses indefinitely. Rare PSSD-like post-discontinuation syndrome in susceptible individuals with protracted neurochemical modification.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Contextual safety check for users with liver history, heavy alcohol use, hepatotoxic stacks, oral 17-AAS exposure, prolonged daily use, or a cautious self-tracking preference. Ordinary low-dose standalone use does not need to be framed as requiring labs.
Useful when baseline liver risk exists, symptoms appear, daily use continues through a full cycle, or ashwagandha is layered into hepatotoxic compounds. Stop and evaluate for jaundice, dark urine, right-upper-quadrant discomfort, or abnormal enzymes.
Recommended for known thyroid disease, thyroid-medication users, hyperthyroid symptoms, or borderline thyroid history. For otherwise healthy users, symptom awareness is usually enough.
Check at 6–8 weeks especially for euthyroid users or those on thyroid medication. Discontinue if T4/T3 rise outside reference range or TSH falls below normal.
For natural-state (non-TRT) users targeting testosterone support — baseline confirms eligibility and provides reference for assessing response at 8–12 weeks.
Confirms elevated cortisol as the target before using ashwagandha for stress management. Users with already-low baseline cortisol risk suppressing an already-suppressed axis.
Avoid With
Do not combine Ashwagandha with the following. Sorted highest-severity first.
Why:Compounded hepatotoxicity — oxymetholone is hepatotoxic via oral steroid pathway; ashwagandha adds glutathione-depletion hepatic load. Combined risk is additive to synergistic.
What to do:Despite animal research showing Withania somnifera may mitigate some oxymetholone-induced pathological changes, community consensus is that the combined hepatic load is unacceptable. Use injectable-only compounds if ashwagandha is desired on cycle.
Why:Ashwagandha independently increases T3 and T4; combined with exogenous thyroid hormone creates compounded stimulation potentially pushing into hyperthyroid range. Medication dose adjustment required.
What to do:Some users combine these successfully with physician monitoring and downward thyroid medication titration. Do not attempt without prescriber involvement and thyroid labs every 4–6 weeks.
Why:Ashwagandha potentiates GABA-A receptor activity — additive sedation risk with benzodiazepines or other GABAergic agents.
What to do:Moderate evening doses of ashwagandha (300 mg) may be acceptable if benzo doses are low and timing is offset; high doses risk excessive CNS depression.
Why:Ashwagandha has immunostimulatory effects (NF-κB, Nrf2, lymphocyte activation) that may counteract immunosuppressant therapy in transplant or autoimmune patients.
What to do:Absolute contraindication in organ transplant recipients. Caution in autoimmune disease.
Why:Cumulative hepatotoxic burden from multiple independently hepatotoxic compounds.
What to do:Run one potentially hepatotoxic compound at a time to maintain attributability of LFT elevations.
Protocols By Goal
Stress/anxiety: choose KSM-66 when the goal is broad stress resilience without heavy sedation; choose Sensoril when sleep pressure is part of the target; choose Shoden when a low-capsule, low-milligram standardized form is preferred. Sleep: Sensoril or evening KSM-66 can pair with glycine and L-theanine, but stop if calm becomes emotional flattening. Natural testosterone: benefit is mainly for non-TRT, stressed, or mildly hypogonadal users; TRT users should not expect a meaningful testosterone lift. Recovery/training: use it as a cortisol and recovery-support tool during defined 8–12 week blocks, not as an anabolic substitute. On-cycle management: only makes sense when the stack is not already hepatotoxic; oral 17-AAS, heavy alcohol, or abnormal liver enzymes move this from a casual adaptogen into an avoid lane.
Dosing Details
Beginner start: 150–250 mg standardized extract in the evening for 2 weeks, then adjust only if the response is clearly useful and mood/thyroid/sleep signals remain clean.
KSM-66: 300 mg/day is the usual entry dose; 600 mg/day is the common upper everyday study dose for stress, performance, and natural-testosterone support. Sensoril: 250–300 mg, usually 30–60 min before sleep when the goal is sedation-leaning stress or sleep support. Shoden: commonly around 120 mg/day because it is a higher-potency standardized extract; treat it as a lower-milligram form, not a weaker product. Raw bulk powder: 3–6 g/day may be needed for equivalent exposure and is less predictable because withanolide content varies. Cycle 8–12 weeks on, then 4 weeks off if using daily. Avoid pre-workout dosing and avoid combining with oral 17-AAS or other hepatotoxic stacks.
Stacks & Alternatives
WADA-compliant natty testosterone stack. Ashwagandha lowers cortisol (seesaw effect), Fadogia and Tongkat Ali support LH/T signaling, Boron displaces SHBG to enhance free T, Magnesium supports overall hormonal function. All PM/evening except Boron any time.
Sleep and recovery stack. Additive GABAergic and parasympathetic activation. Cortisol suppression from ashwagandha + PS, GABA potentiation from glycine + theanine, sleep architecture improvement across all components. Take 30–60 min before sleep.
AM adaptogen priming stack. Rhodiola adds stimulant-free energy; Holy Basil for cortisol; Bacopa for cognition with safer long-term profile. Low ashwagandha dose acceptable in this morning context.
On-cycle cortisol and sleep management. Documented for managing trenbolone-associated sleep disruption, night sweats, and cortisol elevation during cut. Evening only; use liver-enzyme monitoring if hepatic load is already elevated; no concurrent oral 17-AAS.
Alternatives
Stack Cost
Low-to-moderate tax: ashwagandha is OTC, oral, non-suppressive, and beginner-compatible, but it still creates liver, thyroid, CNS/mood, sedation, sourcing, and cycling caveats that wellness marketing often underplays.
The article preserves hepatotoxicity as the serious safety signal, but frames it as uncommon and usually contextual rather than a routine-lab requirement for every ordinary user. The burden escalates with liver disease, oral 17-alpha-alkylated steroids, heavy alcohol, hepatotoxic supplements, symptoms, or prolonged daily use.
The article frames ashwagandha as an active HPA/GABA/5HT1A modulator rather than a neutral calming aid. The same pathways that support stress and sleep can produce paradoxical stimulation, emotional blunting, anhedonia, or rare protracted post-discontinuation syndromes in susceptible users.
Monitoring is contextual: liver enzymes and thyroid labs can change decisions in red-flag users, medication users, hepatotoxic stacks, symptoms, prolonged daily use, or cautious self-tracking, while cortisol and testosterone/LH are goal-tracking tools rather than ordinary-use safety gates.
stackingConflicts names oral 17-AAS, thyroid medications, GABAergic sedatives, immunosuppressants, and other hepatotoxic supplements as relevant conflict lanes. The interaction burden is not broad prescription complexity, but the identified conflicts are consequential.
Product cost is low, but practicalitiesSummary and practicalConsiderations warn that only a minority of products pass third-party testing and that heavy-metal contamination and extract variability matter. The real access burden is sourcing a standardized, COA-backed KSM-66, Sensoril, or comparable extract rather than using random bulk powder.
- ·Counts as a liver-monitoring lane; do not combine with Anadrol, other oral 17-alpha-alkylated steroids, heavy alcohol intake, kava, high-dose green-tea extract, or other hepatotoxic supplements without treating the stack as high-risk.
- ·Counts as a thyroid-modulating lane; users on levothyroxine, liothyronine, desiccated thyroid, or with hyperthyroidism need prescriber oversight or avoidance.
- ·Counts as a CNS/mood/sedation lane; be careful stacking high-dose evening ashwagandha with benzodiazepines, Z-drugs, barbiturates, strong sleep stacks, or other GABAergic sedatives.
- ·Does not consume an androgen, HPTA-suppression, GH/IGF, or injection-logistics lane, so it can sit under many performance stacks when liver, thyroid, and mood monitoring are already accepted.
- ·Use cycle capacity rather than indefinite daily use: the article's 8-12 weeks on and 4 weeks off rule is part of keeping the stack tax moderate.
- ·Contextual liver-enzyme checks when liver history, hepatotoxic stacks, symptoms, prolonged daily use, or cautious self-tracking justify them.
- ·Baseline thyroid panel and 6-8 week follow-up when thyroid symptoms, thyroid medication, hyperthyroid risk, or borderline thyroid status are present.
- ·Mood and pleasure-response monitoring, with discontinuation if emotional flattening or anhedonia appears.
- ·Evening or late-afternoon dosing discipline to avoid morning-cortisol and pre-workout adaptation conflicts.
- ·Structured cycling: 8-12 weeks on, 4 weeks off rather than indefinite daily use.
Ashwagandha is accessible, oral, legal, non-injectable, and non-suppressive, so a low-dose standardized extract is beginner-compatible. The caution is that liver history, thyroid disease or medication, pregnancy, mood flattening, hepatotoxic stacks, and continuous high-dose use can turn a simple trial into a managed context.
- ·Using oral anabolic steroids, heavy alcohol, or other hepatotoxic compounds
- ·Taking thyroid medication or carrying untreated thyroid disease
- ·History of anhedonia, PSSD-like symptoms, bipolar instability, or severe medication-sensitive mood reactions
- ·Pregnant, trying to conceive, lactating, or unable to avoid use during pregnancy
Most users can stop directly because there is no HPTA suppression or receptor-dependent taper requirement, but the article describes anhedonia, emotional blunting, thyroid shifts, and rare PSSD-like reports that can persist weeks to months after discontinuation.
- ·Return of stress, anxiety, or sleep latency if it was masking a real stress load
- ·Transient mood flattening or anhedonia in susceptible users
- ·Need to recheck liver enzymes or thyroid labs if symptoms or abnormal midcycle results appeared
- ·Loss of modest cortisol/testosterone support in natural-state users
Use liver enzymes contextually for liver history, hepatotoxic stacks, symptoms, prolonged daily use, or cautious self-tracking; avoid oral 17-AAS and other hepatotoxic stacks; discontinue and evaluate if ALT/AST exceed 3x ULN or symptoms appear.
Avoid in hyperthyroidism, coordinate with a prescriber when thyroid medication is present, and repeat thyroid labs at 6-8 weeks for daily users with risk factors.
Use the lowest effective dose, cycle rather than running indefinitely, and stop promptly if the effect feels like loss of affect instead of stress relief.
Move dosing to evening, reduce dose, or discontinue if stimulation persists; avoid pre-workout dosing because the article warns against blunting training-adaptation cortisol signaling.
The article's main serious risk is hepatotoxicity, and the strongest stacking redline is compounded hepatic load.
Ashwagandha can increase T3/T4, so users already manipulating thyroid hormone need lab-guided medical oversight or avoidance.
The article marks pregnancy as an absolute contraindication because high-dose animal data raise embryotoxicity concerns and no safe pregnancy dose is established.
The article's CNS concern is not only sedation; it includes emotional blunting, 5HT1A-desensitization framing, and rare persistent post-discontinuation reports.
Practical Setup
Quality matters critically — only approximately 38% of ashwagandha products pass third-party testing; heavy metal contamination from soil accumulation is a documented risk in products from certain Indian subcontinent regions; purchase only standardized extracts (KSM-66, Sensoril, Shoden, or comparable third-party-tested forms) with COAs. Form choice is the main practical decision: KSM-66 is the broad performance/stress default, Sensoril tends to fit sleep or stronger calming use, Shoden is the lower-milligram/high-potency option, and raw powder is least predictable. Biomarkers are contextual: liver enzymes are reasonable for liver history, hepatotoxic stacks, symptoms, prolonged daily use, or cautious self-tracking; thyroid labs matter for thyroid disease, thyroid medication, hyperthyroid symptoms, or borderline thyroid status; cortisol and testosterone/LH are optional goal-tracking tools rather than safety gates. Timing: evening or late-afternoon is the default — preserves morning cortisol peak for alertness and exercise adaptation; pre-workout dosing at 400–600 mg is a poor fit because cortisol suppression may blunt the beneficial training adaptation response. Cycling: 8–12 weeks on, 4 weeks off for daily use; continuous use beyond 12 months at high doses is not supported. Population-specific: natural testosterone benefit requires non-TRT status (TRT users see no meaningful T benefit); HCG monotherapy users may benefit (partial natural state); PCT users: supporting compound weeks 2–4+ alongside SERMs, not replacing SERMs; beginners: 150–250 mg for 2 weeks before escalating to identify individual response profile. Contraindications: hyperthyroidism (absolute); pregnancy (absolute — embryotoxic in high-dose animal studies); active hepatic disease; organ transplant (immunostimulatory); Anadrol and other oral 17-AAS (compounded hepatotoxicity).
Mechanism Deep Dive
Ashwagandha's pharmacological effects operate through four primary molecular pathways: (1) HPA axis modulation — withanolides reduce CRH-mediated cortisol secretion at the hypothalamic-pituitary level, producing 15–30% cortisol reduction. This master mechanism drives stress relief, testosterone support via the cortisol-testosterone seesaw (shared pregnenolone substrate), sleep improvement through reduced late-evening cortisol, and the performance community's on-cycle utility. (2) GABAergic activity — withanolides bind GABA-A receptor sites and potentiate chloride channel conductance, producing anxiolytic and sleep-latency-reducing effects comparable to low-dose benzodiazepine mechanisms. Serotonin increases and cortisol-lowering via reduced HPA responsiveness also occur via this pathway. Sustained 5HT1A receptor desensitization is the proposed mechanism for emotional blunting and the rare PSSD-like syndrome in susceptible individuals. (3) NF-κB inhibition (withaferin-A primary mediator) — reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and drives anti-inflammatory and anti-arthritic effects; also drives preclinical anticancer activity via NHEJ pathway inhibition and apoptosis induction. (4) Nrf2 activation — upregulates glutathione, SOD, and catalase. Paradoxically, withanolides at high concentrations may directly deplete hepatic glutathione — the proposed hepatotoxicity mechanism where the antioxidant effect reverses to a pro-oxidant hepatic burden. Secondary mechanisms: acetylcholinesterase inhibition by withanolide-A (Alzheimer's-relevant, preclinical); NMDA receptor expression reduction; dopaminergic D2 receptor enhancement (anti-Parkinsonian, preclinical); thyroid-stimulating effect (mechanism unclear, distinct from TRH/TSH axis modulation); 5-alpha reductase modulation affecting DHT/T ratio; norepinephrine and sympathetic tone modulation. CYP450 interactions (3A4, 2D6 inhibition at high concentrations) explain herb-drug interaction risk and much of the individual response variability. Bioavailability ~20%; peak plasma ~2 hours; withanolide half-life ~7–10 hours extrapolated from cortisol curves.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Cortisol reduction of 15–30% in chronically stressed adults on 300–600 mg standardized extract for 8–12 weeks
Consistent finding across multiple RCTs per Julian Douwes M.D. review; one RCT showed significant cortisol reduction with no corresponding improvement in perceived stress — cortisol and subjective stress are dissociable outcomes
Approximately 1.5 kg muscle mass gain vs 0.5 kg placebo and significant strength improvements in resistance-trained men on 600 mg KSM-66/day for 8 weeks
Wankhede et al., Journal of the International Society of Sports Nutrition 2015 — foundational study for performance community adoption; muscle damage markers also reduced
Testosterone increases of 10–22% in hypogonadal or chronically stressed non-TRT men on 300–600 mg KSM-66 daily
Effect driven by cortisol-testosterone seesaw mechanism; not applicable to TRT users where endogenous T production is suppressed regardless of cortisol
Significant T4 and T3 increase at 600 mg/day in thyroid-compromised individuals; subclinical hypothyroidism normalization
Clinically relevant both ways — beneficial for hypothyroid users, potentially harmful for euthyroid users taking daily doses without thyroid monitoring
Cushingoid features from approximately 950 mg/day ashwagandha held for more than 12 months, not fully reversing at 3 months off
Establishes upper risk boundary for continuous high-dose use; supports cycling rather than indefinite high-dose daily use; published case per biomogging.com
Significant improvements in FSFI scores (arousal, lubrication, orgasm, satisfaction) with 300 mg Sensoril twice daily over 8 weeks
No androgenic or hormonal adverse effects reported; one of the more specific female-population RCTs for ashwagandha
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.